Fixed Dosing of Monoclonal Antibodies in Oncology.

about

Fixed Dosing of Monoclonal Antibodies in Oncology.

Item

http://www.wikidata.org/entity/Q38654371

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Fixed Dosing of Monoclonal Antibodies in Oncology.

@en

type

Item

label

Fixed Dosing of Monoclonal Antibodies in Oncology.

@en

prefLabel

Fixed Dosing of Monoclonal Antibodies in Oncology.

@en

P1476

Fixed Dosing of Monoclonal Antibodies in Oncology.

@en

P2093

Alwin D R Huitema

http://www.w3.org/2001/XMLSchema#string

Emile E Voest

http://www.w3.org/2001/XMLSchema#string

Jan H M Schellens

http://www.w3.org/2001/XMLSchema#string

Jeroen J M A Hendrikx

http://www.w3.org/2001/XMLSchema#string

John B A G Haanen

http://www.w3.org/2001/XMLSchema#string

Jos H Beijnen

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

P2860

Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors

Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma.

Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.

Dosage adjustments for antibacterials in obese patients: applying clinical pharmacokinetics.

Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma

Body surface area as a determinant of pharmacokinetics and drug dosing.

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

The use of body surface area as a criterion of drug dosage in cancer chemotherapy.

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

P31

scholarly article

review article

P356

10.1634/THEONCOLOGIST.2017-0167

http://www.w3.org/2001/XMLSchema#string

P577

2017-07-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28754722

http://www.w3.org/2001/XMLSchema#string

P921

globulins

monoclonal antibody

blood proteins

P932

5634778

http://www.w3.org/2001/XMLSchema#string